According to a letter released by the FDA, the advertisement makes false or misleading claims about the drug’s efficacy in treating migraine pain. The agency added that the ad exaggerates the speed and extent of Ubrelvy’s benefits, suggesting the medication can eliminate migraine pain more quickly and effectively than shown in clinical trials.
The FDA also noted that using a celebrity like Williams amplifies the misleading nature of the ad, making the claims seem more credible to audiences.
Clinical studies cited by the FDA show that only around 19% to 22% of patients experienced pain relief within two hours of taking Ubrelvy, significantly lower than displayed in the advertisement.
The FDA has requested that AbbVie halt distribution of the ad and provide a corrective plan within 15 working days to address the violations.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
